Summary of Significant Accounting Policies - Schedule of Percentage of Revenues and Accounts Receivables from Customers (Details) - Customer Concentration Risk |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
|
| Revenue | VA MVP | |||
| Summary Of Significant Accounting Policies [Line Items] | |||
| Concentration risk percentage | 13.00% | 13.00% | 53.00% |
| Revenue | Natera Inc. | |||
| Summary Of Significant Accounting Policies [Line Items] | |||
| Concentration risk percentage | 43.00% | 41.00% | 10.00% |
| Revenue | Merck & Co., Inc. | |||
| Summary Of Significant Accounting Policies [Line Items] | |||
| Concentration risk percentage | 11.00% | ||
| Accounts Receivable | Natera Inc. | |||
| Summary Of Significant Accounting Policies [Line Items] | |||
| Concentration risk percentage | 36.00% | 43.00% | |
| Accounts Receivable | Pfizer Inc. | |||
| Summary Of Significant Accounting Policies [Line Items] | |||
| Concentration risk percentage | 10.00% | ||
| Accounts Receivable | GSK plc | |||
| Summary Of Significant Accounting Policies [Line Items] | |||
| Concentration risk percentage | 12.00% | ||